Home › Funds › NEXTBio Capital Management LP › RYTM
NEXTBio Capital Management LP position in RYTM
RHYTHM PHARMACEUTICALS INC · Health Care
NEXTBio Capital Management LP reported holding 131,758 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$12.5M, representing 5.46% of its reported portfolio and ranking #4 among its reported holdings. NEXTBio Capital Management LP has disclosed RYTM holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How NEXTBio Capital Management LP's RYTM position evolved
NEXTBio Capital Management LP first disclosed a stake in RYTM in Q4 2025 at 67,586 shares (US$7.2M). The position peaked in Q2 2026 at 131,758 shares, worth US$14.6M. Across 4 filings, NEXTBio Capital Management LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 131,758 shares valued at US$12.5M. Notable position changes include a 87% increase in Q1 2026 (shares rose 28% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 67.59K | $7.23M | New |
| Q1 2026 | 126.08K | $10.97M | Add |
| Q2 2026 | 131.76K | $14.63M | Add |
| Q3 2026 | 131.76K | $12.55M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RYTM and 13F data
RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 43 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RYTM
- RA CAPITAL MANAGEMENT, L.P. 6.67M sh · $740.22M · Q2 2026
- BAKER BROS. ADVISORS LP 5.60M sh · $622.27M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.59M sh · $287.16M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 2.48M sh · $236.20M · Q3 2026
- Polar Capital Holdings Plc 1.66M sh · $184.71M · Q2 2026
- Checkpoint Capital L.P. 1.19M sh · $131.68M · Q2 2026
- Siren, L.L.C. 1.09M sh · $103.43M · Q3 2026
- Rock Springs Capital Management LP 692.60K sh · $76.90M · Q2 2026
- Integral Health Asset Management, LLC 550.00K sh · $61.07M · Q2 2026
- Sofinnova Investments, Inc. 408.03K sh · $45.30M · Q2 2026
More on NEXTBio Capital Management LP
FAQ
How long has NEXTBio Capital Management LP held RYTM?
NEXTBio Capital Management LP has disclosed RYTM holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is NEXTBio Capital Management LP's current position in RYTM?
As of Q3 2026, NEXTBio Capital Management LP holds 131.76K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $12.55M, representing 5.46% of its reported portfolio and ranking #4.
Has NEXTBio Capital Management LP been buying or selling RYTM?
In the latest 13F filing (Q3 2026), NEXTBio Capital Management LP held unchanged its position in RYTM. The position peaked in Q2 2026 at 131.76K shares.
Which other funds hold RYTM?
Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.